海角破解版

EasySep? Human CD8 Positive Selection Kit II

Immunomagnetic positive selection of human CD8+ T cells

EasySep? Human CD8 Positive Selection Kit II

Immunomagnetic positive selection of human CD8+ T cells

Catalog #
(Select a product)
Immunomagnetic positive selection of human CD8+ T cells
Request Pricing Request Pricing

Product Advantages


  • Fast and easy-to-use

  • Up to 99% purity

  • No columns required

What's Included

  • EasySep? Human CD8 Positive Selection Kit II (Catalog #17853)
    • EasySep? Human CD8 Positive Selection Cocktail II, 1 mL
    • EasySep? Dextran RapidSpheres? 50100, 1 mL
  • EasySep? Human CD8 Positive Selection Kit II (Catalog #100-0699)
    • EasySep? Human CD8 Positive Selection Cocktail II, 1 x 10 mL
    • EasySep? Dextran RapidSpheres? 50103, 1 x 1 mL
  • RoboSep? Human CD8 Positive Selection Kit II (Catalog #17853RF)
    • EasySep? Human CD8 Positive Selection Cocktail II, 1 mL
    • EasySep? Dextran RapidSpheres? 50100, 1 mL
    • RoboSep? Buffer (Catalog #20104)
    • RoboSep? Filter Tips (Catalog #20125)
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

Overview

Isolate highly purified human CD8+ T cells from fresh or previously frozen human peripheral blood mononuclear cells (PBMCs) or washed leukapheresis samples by immunomagnetic positive selection, with the EasySep? Human CD8 Positive Selection Kit II. Widely used in published research for more than 20 years, EasySep? combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.

In this EasySep? positive selection procedure, desired cells are labeled with antibody complexes recognizing CD8 and magnetic particles. The cocktail in this kit also contains an antibody to human Fc receptor to prevent non-specific binding. Labeled cells are separated using an EasySep? magnet and by simply pouring or pipetting off the unwanted cells. The cells of interest remain in the tube. Following magnetic cell isolation in as little as 15 minutes, the desired CD8+ T cells are ready for downstream applications such as flow cytometry, culture, or DNA/RNA extraction. The CD8 antigen is expressed on cytotoxic T cells and weakly on a subset of NK cells.

This product replaces the EasySep? Human CD8 Positive Selection Kit (Catalog #18053) for even faster cell isolations.

For large-scale isolation of human CD8+ cells from leukapheresis samples, see the large-format (1x10^10 cells) kit (Catalog #100-0699).

Learn more about how immunomagnetic EasySep? technology works or how to fully automate immunomagnetic cell isolation with RoboSep?. Alternatively, choose ready-to-use, ethically sourced, primary Human Peripheral Blood CD14+ Monocytes, Frozen isolated with EasySep? Human CD8 Positive Selection Kit II. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.

Magnet Compatibility
? EasySep? Magnet (Catalog #18000)
? “The Big Easy” EasySep? Magnet (Catalog #18001)
? EasyPlate? EasySep? Magnet (Catalog #18102)
? EasyEights? EasySep? Magnet (Catalog #18103)
? Easy 50 EasySep? Magnet (Catalog #18002)
? RoboSep?-S (Catalog #21000)
? Easy 250 EasySep? Magnet (Catalog #100-0821)
Subtype
Cell Isolation Kits
Cell Type
T Cells, T Cells, CD8+
Species
Human
Sample Source
PBMC
Selection Method
Positive
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Immunology

Data Figures

Typical EasySep? Human CD8 Positive Selection Profile

Figure 1. Typical EasySep™ Human CD8 Positive Selection Profile

Starting with a single cell suspension of human PBMCs, the CD8+ cell content of the isolated fraction is typically 96.5 ± 2.4% (mean ± SD) using "The Big Easy" EasySep™ Magnet.

FACS Data for Anti-Human CD8a Antibody, Clone RPA-T8, PerCP-Cy55-Conjugated

Figure 2. FACS Data for Anti-Human CD8a Antibody, Clone RPA-T8, PerCP-Cy55-Conjugated

(A) Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) labeled with Anti-Human CD8a Antibody, Clone RPA-T8, PerCP-Cy5.5 (Catalog #60022PS; filled histogram) or a mouse IgG1, kappa isotype control antibody, PerCP-Cy5.5 (solid line histogram).

(B) Flow cytometry analysis of human PBMCs processed with the EasySep™ Human CD8 Positive Selection Kit (Catalog #17853) and labeled with Anti-Human CD8a Antibody, Clone RPA-T8, PerCP-Cy5.5. Histograms show labeling of PBMCs (Start) and isolated cells (Isolated). Labeling of start cells with a mouse IgG1, kappa PerCP-Cy5.5 isotype control antibody is shown (solid line histogram).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
17853RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17853RF
Lot #
All
Language
Multi
Document Type
Product Name
Catalog #
17853
Lot #
All
Language
Multi
Document Type
Product Name
Catalog #
17853
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17853
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0699
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17853RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17853RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17853RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17853
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17853
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0699
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Frequently Asked Questions

Can EasySep™ be used for either positive or negative selection?

Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).

How does the separation work?

Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Can EasySep™ be used to isolate rare cells?

Yes. We recommend a cell concentration of 2x108 cells/mL and a minimum working volume of 100 µL. Samples containing 2x107 cells or fewer should be suspended in 100 µL of buffer.

Are the EasySep™ magnetic particles FACS-compatible?

Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.

Can the EasySep™ magnetic particles be removed after enrichment?

No, but due to the small size of these particles, they will not interfere with downstream applications.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

For positive selection, can I perform more than 3 separations to increase purity?

Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.

How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?

Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.

If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.

Publications (27)

Identification and characterization of a ubiquitin E3 RING ligase of the Chlamydia-like bacterium Simkania negevensis E-M. H?rner et al. PLOS Pathogens 2025 Nov

Abstract

In the arms race between a pathogen and the host, the defense mechanisms of the host cell, including the ubiquitin system, are often counteracted by bacteria. Simkania negevensis (Sne), an obligate intracellular Chlamydia-like bacterium connected with respiratory diseases, possesses numerous deubiquitinases, but not much is known about its other ubiquitin-modifying enzymes. Sne infects a wide range of hosts, developing inside a tubular vacuole in close contact with the host endoplasmic reticulum (ER) and mitochondria. Our study describes an uncharacterized Sne ubiquitin E3 RING-ligase (SNE_A12920 or SneRING), which primarily generates K63- and K11-linked ubiquitin chains and preferentially interacts with UbcH5b and UBE2T E2 enzymes. SneRING is expressed upon infection of various human cell lines, as well as amoebae. We show that a portion of the expressed SneRING co-localizes with mitochondria and ER and that the SneRING interactome includes mitochondrial and ER proteins involved in organelle morphology and stress response. Our work offers an initial characterization of a bacterial RING ligase potentially involved in the host cell remodeling to accommodate the unique intracellular lifestyle of Sne. Author summaryUbiquitination is a protein modification system that regulates protein degradation, localization, or interactions. As such, ubiquitination has many important functions in cell signalling, and its dysregulation can lead to cancer and neurodegenerative diseases. Bacteria that live and develop inside human or other eukaryotic cells, such as Chlamydia, often modulate the ubiquitination system to ensure their own survival. Simkania negevensis is a Chlamydia-like bacterium connected to respiratory diseases in humans. We have discovered a novel enzyme expressed by these bacteria that can ubiquitinate other proteins and thus potentially modify host cell processes that would otherwise hinder infection. In this work, we explore the function of this enzyme and determine its possible cellular localization, as well as some of the proteins it interacts with. Our study provides new insights into how bacterial pathogens adapt to and manipulate host cells using one of the major cell function regulatory systems.
Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia C. Wiggers et al. Nature Communications 2025 Nov

Abstract

Changes in the immune microenvironment are frequent in cancers occurring in adult patients, yet our understanding of the pediatric cancer immune microenvironment and its clinical relevance is limited. We investigate the immune microenvironment in pediatric T cell acute lymphoblastic leukemia (T-ALL), using single-cell CITE-seq and immune repertoire analyses. We identify a T-ALL subgroup characterized by a remodeled immune microenvironment, which is associated with adverse clinical outcome in minimal residual disease low patients. This adverse immune landscape is dominated by the presence of a population of non-malignant CD4-CD8-TCRαβ T cells that interact with CXCL16 expressing non-classical monocytes. Leukemia cell intrinsic transcriptional rewiring in these patients is associated with activation of Rap1 signaling. Inhibiting Rap1 signaling results in increased sensitivity to the BCL2/BCL-XL inhibitor navitoclax. Our study provides insights into the immune microenvironment of pediatric hematologic malignancies, forming the basis for identifying potential (immuno) therapeutic targets and risk stratification for treatment. Understanding of the immune microenvironment in pediatric acute T cell lymphoblastic leukemia is limited. By analyzing single-cell transcriptome, surface protein expression and immune repertoire data, the authors here identify non-malignant CD4-CD8- TCRαβ T cells that are present in a subset of patients with Rap1 signaling in leukemia cells and are associated with adverse clinical outcome in patients with low minimal residual disease.
Modeling mesenchymal stromal cell support to hematopoiesis within a novel 3D artificial marrow organoid system Scientific Reports 2025 Jul

Abstract

The human bone marrow (BM) microenvironment involves hematopoietic and non-hematopoietic cell subsets organized in a complex architecture. Tremendous efforts have been made to model it in order to analyze normal or pathological hematopoiesis and its stromal counterpart. Herein, we report an original, fully-human in vitro 3D model of the BM microenvironment dedicated to study interactions taking place between mesenchymal stromal cells (MSC) and hematopoietic stem and progenitor cells (HSPC) during the hematopoietic differentiation. This fully-human Artificial Marrow Organoid (AMO) model is highly efficient to recapitulate MSC support to myeloid differentiation and NK cell development from the immature CD34?+?HSPCs to the most terminally differentiated CD15?+?polymorphonuclear neutrophils, CD64?+?monocytes or NKG2A-KIR2D?+?CD57?+?NK subset. Lastly, our model is suitable for evaluating anti-leukemic NK cell function in presence of therapeutic agents. Overall, the AMO is a versatile, low cost and simple model able to recapitulate normal hematopoiesis and allowing more physiological drug testing by taking into account both immune and non-immune BM microenvironment interactions.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-07717-9.